Related Experiment Video
Updated: May 27, 2026
Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Highly sensitive and rapid determination of Coxsackievirus A16 using restriction endonuclease-mediated reverse
Qi Liang1,2,3, Yumei Cao1,4, Xujian Zhang1,5
1Department of Clinical Laboratory, The First People's Hospital of Guiyang, Guiyang, Guizhou, 550004, People's Republic of China.
Insights
A new diagnostic method, Coxsackievirus A16-E-RT-MCDA, offers sensitive, rapid, and specific detection of CVA16. This molecular approach is crucial for managing hand, foot, and mouth disease in young children.
Area of Science:
- Molecular Diagnostics
- Virology
- Infectious Diseases
Background:
- Coxsackievirus A16 (CVA16) is a primary cause of hand, foot, and mouth disease in infants and toddlers.
- Effective antiviral drugs and vaccines for CVA16 are currently unavailable.
- Sensitive, specific, and rapid diagnostic methods are essential for CVA16 prevention and management.
Purpose of the Study:
- To develop a novel molecular diagnostic approach for sensitive, rapid, and specific identification of CVA16.
- To establish a real-time fluorescence technique coupled with reverse transcription multiple cross-displacement amplification (RT-MCDA) for CVA16 detection.
Main Methods:
- Designed a unique set of primers targeting the VP1 gene of CVA16 for the RT-MCDA assay.
- Optimized reaction conditions for CVA16-E-RT-MCDA to 63°C for 35 minutes.
- Evaluated the assay's limit of detection, specificity, and anti-interference capabilities.
Main Results:
- The CVA16-E-RT-MCDA assay achieved a limit of detection of 14 copies/µL for the CVA16 RNA standard.
- The assay demonstrated high specificity and anti-interference properties.
- Successful confirmation of the method's applicability using clinical samples from suspected CVA16 infections.
Conclusions:
- The developed CVA16-E-RT-MCDA assay is sensitive, specific, and rapid for CVA16 detection.
- This assay represents a promising diagnostic tool for clinical applications in managing CVA16 infections.
Background:
As a major etiological agent of hand, foot, and mouth disease in humans, Coxsackievirus A16 (CVA16) exerts a detrimental impact on the health of infants and toddlers. In the absence of effective antiviral drugs and vaccines targeting CVA16, a diagnostic strategy with sensitivity, specificity and rapid response is indispensable for the prevention and management of CVA16 infection.
Results:
In this study, a novel molecular diagnostic approach, coupling real-time fluorescence technique with reverse transcription multiple cross-displacement amplification (RT-MCDA), was developed for the sensitive, rapid, and specific identification of CVA16 (termed CVA16-E-RT-MCDA). To construct the system, a unique set of CVA16-E-RT-MCDA primers was successfully designed targeting the VP1 gene of CVA16, and the optimal conditions for CVA16-E-RT-MCDA were determined to be 63 ℃ for 35 min. The limit of detection for the CVA16-E-RT-MCDA assay was 14 copies/µL (approximately 70 copies per reaction) for the RNA standard template of CVA16. The CVA16-E-RT-MCDA assay exhibited high specificity and anti-interference. The findings demonstrated that the applicability of the CVA16-E-RT-MCDA method was promptly and successfully confirmed using clinical samples from patients with suspected CVA16 infections.
Conclusions:
The CVA16-E-RT-MCDA assay established in the present study exhibits sensitivity, specificity and rapidity for CVA16 detection, rendering it a promising diagnostic tool for clinical applications.
